FDA Approved: DARZALEX FASPRO — Supplemental Application (Janssen Biotech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for DARZALEX FASPRO submitted by Janssen Biotech, Inc. to modify/expand its labeling or indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))

Snippet

SUPPL AP for DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))